Stock Analysis
- Hong Kong
- /
- Medical Equipment
- /
- SEHK:2297
Rainmed Medical Full Year 2023 Earnings: CN¥0.10 loss per share (vs CN¥1.50 loss in FY 2022)
Rainmed Medical (HKG:2297) Full Year 2023 Results
Key Financial Results
- Revenue: CN¥73.2m (down 12% from FY 2022).
- Net loss: CN¥115.8m (loss narrowed by 91% from FY 2022).
- CN¥0.10 loss per share (improved from CN¥1.50 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Rainmed Medical shares are up 4.8% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Rainmed Medical has 3 warning signs (and 1 which makes us a bit uncomfortable) we think you should know about.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:2297
Rainmed Medical
Operates as a vascular interventional surgical robotics company in China and internationally.